Vertex Pharmaceuticals Inc (VRTX) stock
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3030% above fair value
$536.45+2.25 (+0.42%)
Close on Nov 18, 2026Market cap $135.97BP/E 31.2Yield –
Vertex Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Vertex Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was $3.80B, up 8.5% year over year. For fiscal 2025 it was $3.19B. The highest annual figure on record is $3.93B in fiscal 2022.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.19B | – |
| FY2024 | Dec 31, 2024 | -$790.30M | -123.7% |
| FY2023 | Dec 31, 2023 | $3.34B | -15.0% |
| FY2022 | Dec 31, 2022 | $3.93B | +63.0% |
| FY2021 | Dec 31, 2021 | $2.41B | -19.5% |
| FY2020 | Dec 31, 2020 | $2.99B | +100.4% |
| FY2019 | Dec 31, 2019 | $1.49B | +27.2% |
| FY2018 | Dec 31, 2018 | $1.17B | +57.6% |
| FY2017 | Dec 31, 2017 | $745.52M | +315.2% |
| FY2016 | Dec 31, 2016 | $179.54M | – |
| FY2015 | Dec 31, 2015 | -$410.73M | – |
| FY2014 | Dec 31, 2014 | -$624.31M | – |
| FY2013 | Dec 31, 2013 | -$112.06M | -157.0% |
| FY2012 | Dec 31, 2012 | $196.70M | +80.2% |
| FY2011 | Dec 31, 2011 | $109.14M | – |
| FY2010 | Dec 31, 2010 | -$673.50M | – |
| FY2009 | Dec 31, 2009 | -$451.08M | – |
| FY2008 | Dec 31, 2008 | -$258.66M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.01B | +9.3% |
| Q1 FY2026 | Mar 31, 2026 | $1.29B | +66.4% |
| Q4 FY2025 | Dec 31, 2025 | $348.60M | -29.1% |
| Q3 FY2025 | Sep 30, 2025 | $1.14B | -12.5% |
| Q2 FY2025 | Jun 30, 2025 | $927.40M | – |
| Q1 FY2025 | Mar 31, 2025 | $778.20M | -37.2% |
| Q4 FY2024 | Dec 31, 2024 | $492.00M | +178.8% |
| Q3 FY2024 | Sep 30, 2024 | $1.30B | +6.1% |
| Q2 FY2024 | Jun 30, 2024 | -$3.82B | -455.7% |
| Q1 FY2024 | Mar 31, 2024 | $1.24B | +44.3% |
| Q4 FY2023 | Dec 31, 2023 | $176.50M | -83.1% |
| Q3 FY2023 | Sep 30, 2023 | $1.23B | +36.2% |
| Q2 FY2023 | Jun 30, 2023 | $1.07B | -1.1% |
| Q1 FY2023 | Mar 31, 2023 | $857.80M | -3.9% |
| Q4 FY2022 | Dec 31, 2022 | $1.04B | +12.0% |
| Q3 FY2022 | Sep 30, 2022 | $901.30M | +3.0% |
| Q2 FY2022 | Jun 30, 2022 | $1.09B | – |
| Q1 FY2022 | Mar 31, 2022 | $892.60M | +5.0% |
| Q4 FY2021 | Dec 31, 2021 | $933.20M | +110.3% |
| Q3 FY2021 | Sep 30, 2021 | $874.80M | +19.4% |
| Q2 FY2021 | Jun 30, 2021 | -$249.60M | -124.5% |
| Q1 FY2021 | Mar 31, 2021 | $850.10M | +6.8% |
| Q4 FY2020 | Dec 31, 2020 | $443.84M | +3.4% |
| Q3 FY2020 | Sep 30, 2020 | $732.95M | +136.1% |
| Q2 FY2020 | Jun 30, 2020 | $1.02B | +128.1% |
| Q1 FY2020 | Mar 31, 2020 | $796.25M | +159.6% |
| Q4 FY2019 | Dec 31, 2019 | $429.27M | +43.6% |
| Q3 FY2019 | Sep 30, 2019 | $310.50M | -13.9% |
| Q2 FY2019 | Jun 30, 2019 | $447.39M | +53.2% |
| Q1 FY2019 | Mar 31, 2019 | $306.74M | +37.3% |
| Q4 FY2018 | Dec 31, 2018 | $298.93M | +62.0% |
| Q3 FY2018 | Sep 30, 2018 | $360.44M | +153.6% |
| Q2 FY2018 | Jun 30, 2018 | $292.09M | +77.8% |
| Q1 FY2018 | Mar 31, 2018 | $223.38M | -12.3% |
| Q4 FY2017 | Dec 31, 2017 | $184.53M | +42.0% |
| Q3 FY2017 | Sep 30, 2017 | $142.13M | +174.5% |
| Q2 FY2017 | Jun 30, 2017 | $164.28M | – |
| Q1 FY2017 | Mar 31, 2017 | $254.59M | – |
| Q4 FY2016 | Dec 31, 2016 | $129.94M | – |
| Q3 FY2016 | Sep 30, 2016 | $51.77M | – |
See a number that looks wrong?